
D. E. Shaw Research (DESRES) is a scientific research company that utilizes paradigm-shifting computational technologies to reshape the drug discovery process. They develop specialized supercomputers, notably the Anton series, which execute molecular dynamics (MD) simulations at speeds significantly exceeding general-purpose supercomputers. These simulations provide an ultra-high-resolution view of biological molecule interactions, revealing phenomena previously unseen. DESRES also employs machine learning and other advanced methodologies to identify new therapeutic strategies and design targeted drugs. Their efforts have led to seven clinical-stage drugs, three developed independently and four in collaboration with Relay Therapeutics. The company focuses on elucidating molecular mechanisms of diseases, identifying new drug targets, and creating novel therapeutics for conditions such as chronic inflammatory, autoimmune, respiratory, and oncological diseases.

D. E. Shaw Research (DESRES) is a scientific research company that utilizes paradigm-shifting computational technologies to reshape the drug discovery process. They develop specialized supercomputers, notably the Anton series, which execute molecular dynamics (MD) simulations at speeds significantly exceeding general-purpose supercomputers. These simulations provide an ultra-high-resolution view of biological molecule interactions, revealing phenomena previously unseen. DESRES also employs machine learning and other advanced methodologies to identify new therapeutic strategies and design targeted drugs. Their efforts have led to seven clinical-stage drugs, three developed independently and four in collaboration with Relay Therapeutics. The company focuses on elucidating molecular mechanisms of diseases, identifying new drug targets, and creating novel therapeutics for conditions such as chronic inflammatory, autoimmune, respiratory, and oncological diseases.